Page 117 - Haematologica Vol. 107 - September 2022
P. 117
ARTICLE - iLLUMINATE: final analysis C. Moreno et al.
Figure 7. Prevalence of most common adverse events of any grade (≥20%) and grade ≥3 adverse events (≥3%) over time in patients treated with ibrutinib plus obinutuzumab.
Haematologica | 107 September 2022
2116
